EU Needs More Teamwork On Drug Pricing & Access
HTA, Generics and Biosimilars Are Also In The Frame
Executive Summary
EU member states are being urged by the European Commission to cooperate more closely on pricing and reimbursement, managed access deals and policies to promote generics and biosimilars.
You may also be interested in...
EU Ministers To Debate Pharma ‘Market Failures And High Prices’
Varying levels of access to medicines across the EU are the result of market failures, high prices and pharmaceutical companies’ marketing strategies, says the Council of the EU, which will discuss these issues at the next meeting of European health ministers.
Changes To EU Pharma Reform: More Questions Than Answers?
In the first of a series of articles on the future direction of the EU pharmaceutical reform proposals, the Pink Sheet looks at the new uncertainties created for the drug industry after the European Parliament voted through a series of amendments in the area of regulatory data protection.
Post-Brexit UK Risks Being ‘Left Out In The Cold’ As EU Coordinates Action On Shortages
The UK is not alone in experiencing drug shortages, as data from across Europe show, but its departure from the EU makes it more difficult to respond to supply chain pressures, according to new research.